american brivision (holding) corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the united states. the company is developing abv-1501, a combination therapy for triple negative breast cancer; abv-1504 for major depressive disorders; abv-1505 for attention deficit hyperactivity disorder; abv-1703 for the treatment of pancreatic cancer; abv-1702 to treat myelodysplastic syndromes; and abv-1601 for treating depression in cancer patients. it has a co-development agreement with rgene corporation; collaboration agreement with biohopeking corporation to develop abv-1501; and collaborative agreement with biofirst corporation to co-develop bfc-1401 vitreous substitute for vitrectom; and license with biofirst corporation to research and develop a medical device, abv-1701 vitargus for the treatment of retinal detachment or vitreous hemorrhage. the company was founded in 2015 and is based in fremont, california. american br
Company profile
Ticker
ABVC
Exchange
Website
CEO
Howard Doong
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
American BriVision (Holding) Corp, Ecology Coatings, Inc., ECOLOGY COATINGS, INC., METU BRANDS, INC., OCIS CORP
SEC CIK
Corporate docs
Subsidiaries
AiBtl BioPharma Inc. • American BriVision Corporation • BioKey, Inc. • BioLite Holding, Inc. • BioLite BVI, Inc. • BioLite, Inc. ...
IRS number
260014658
ABVC stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
19 Apr 24
8-K
Entry into a Material Definitive Agreement
17 Apr 24
424B4
Prospectus supplement with pricing info
5 Apr 24
EFFECT
Notice of effectiveness
2 Apr 24
8-K
Entry into a Material Definitive Agreement
26 Mar 24
DEFA14A
Additional proxy soliciting materials
25 Mar 24
S-1/A
IPO registration (amended)
22 Mar 24
10-K/A
2023 FY
Annual report (amended)
14 Mar 24
DEFA14A
Additional proxy soliciting materials
14 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
14 Mar 24
Latest ownership filings
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G
Lind Global Fund II LP
7 Aug 23
3
Shuling Jiang
12 Jul 22
SC 13D
Jiang Shuling
12 Jul 22
3
Chihliang An
31 Mar 22
3
Norimi Sakamoto
10 Dec 21
3
Yoshinobu Odaira
10 Dec 21
3
Tsung Shann Jiang
15 Nov 21
3
Shin-Yu Miao
15 Nov 21
3
Shih-Chen Tseng
15 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.12 mm | 1.12 mm | 1.12 mm | 1.12 mm | 1.12 mm | 1.12 mm |
Cash burn (monthly) | (no burn) | 70.77 k | 1.12 mm | 920.57 k | 452.98 k | 351.45 k |
Cash used (since last report) | n/a | 472.87 k | 7.50 mm | 6.15 mm | 3.03 mm | 2.35 mm |
Cash remaining | n/a | 648.07 k | -6.38 mm | -5.03 mm | -1.91 mm | -1.23 mm |
Runway (months of cash) | n/a | 9.2 | -5.7 | -5.5 | -4.2 | -3.5 |
Institutional ownership, Q2 2023
5.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 8 |
Opened positions | 2 |
Closed positions | 3 |
Increased positions | 1 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 304.15 mm |
Total shares | 588.39 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 387.51 k | $201.31 mm |
Geode Capital Management | 139.28 k | $71.03 mm |
Two Sigma Investments | 22.10 k | $11.48 mm |
NTRS Northern Trust | 18.42 k | $9.57 mm |
Tower Research Capital | 13.88 k | $7.22 mm |
BLK Blackrock | 5.81 k | $3.02 mm |
Spotlight Asset | 1.00 k | $520.00 k |
RY Royal Bank Of Canada | 383.00 | $0.00 |
Proequities | 0.00 | $0.00 |
News
AiBtl BioPharma Inc. Acquired TT Life Company, Valued At $8.33M, With 1.66M AiBtl Shares At $5 per Share
18 Apr 24
ABVC BioPharma Executes A Global Licensing Definitive Agreement For The Treatment Of NSCLC, Expecting Aggregate Income Of $13.75M And Royalties Of Up To $12.50M
17 Apr 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
10 Apr 24
Market-Moving News for April 10th
10 Apr 24
ABVC BioPharma Executes A Global Licensing Term Sheet For Oncology/Hematology Products, Expecting Licensing Income Of $55M And Royalties Of Up To $50M
10 Apr 24
Press releases
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
18 Apr 24
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
10 Apr 24
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
26 Mar 24
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
14 Mar 24
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
12 Feb 24